Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors
Executive Summary
All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.
You may also be interested in...
Blueprint RETreats As It Sells US Gavreto Rights To Rigel
After sales of the RET inhibitor have been commercially disappointing, Blueprint said it is selling US rights to the drug to Rigel for $15m up front and potentially more than $100m in milestones.
Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
$435m Impairment Loss Hits Astellas As Evrenzo Falters, Asset, Deal Dropped
Japanese major’s profit figures for fiscal year just ended will be hit by multiple accounting decisions related to sales, pipeline and partnerships.